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INTRODUCTION 
Ulcerative colitis (colitis ulcerosa, UC) is a chronic idiopathic inflammatory disease of the 
gastrointestinal tract that affects the large bowel and is a major disorder under the broad group of 
conditions termed inflammatory bowel diseases (IBDs).  
Etiopathogenesis of ulcerative colitis largely remains hypothetical. It arises from a complex 
interaction between genetic, immune and environmental factors. Inflammation first affects the 
rectum and extends proximally along a variable length of the colon. In most of the cases, the 
disease follows a chronic relapsing, remitting course. Treatment is mainly immunosuppressive. 
Control of disease includes long term medical management and regular monitoring for 
complications. 
Enteric infections are known to be associated with exacerbations of UC. India, being a tropical 
country has a high prevalence of enteric pathogens. There is scant literature from India on what 
are the interactions of enteric pathogens with disease severity of UC.  
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AIM OF THE STUDY 
To perform a prospective cross-sectional observational study in patients with ulcerative colitis  
- To determine whether there is any association between intestinal infection (with 
parasites, cytomegalovirus or Clostridium difficile) and clinical disease severity in 
patients with ulcerative colitis 
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REVIEW OF LITERATURE
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HISTORY 
Samuel Wilks, in 1859, is credited to be the first person to describe a condition which he called 
“Idiopathic colitis”, that was distinct from the then more common bacillary dysentery1. He 
reported the pathologic finding of dilated and thinned colon with severe pancolonic inflammation 
in a patient with this condition2. In 1909, Hawkins described the chronic and relapsing nature of 
the disease course and the “stealthy hemorrhage” onset of distal disease, in which bleeding per 
rectum often occurred in the presence of constipation3. In that same year, Sir Arthur Hurst gave a 
more elaborate description of UC, including its sigmoidoscopic appearances and differentiation 
from bacillary dysentery4. In 1913, Brown proposed ileostomy as a treatment modality, diverting 
the fecal stream to allow ulcers to heal5. It was only in 1940 that sulfasalazine was introduced as 
a treatment modality for UC6,7. In 1950, Truelove and Witts proved steroids as effective medical 
treatment8. After the discovery of deoxyribonucleic acid (DNA) in 1953 by Watson and Crick9, 
there was better understanding regarding the genetic and molecular basis of UC.  
 
EPIDEMIOLOGY 
The incidence and prevalence of UC vary with geographic location and ethnicity. Rigorous 
epidemiologic studies have been limited by several potential issues: Diagnosis of UC may be 
difficult due to its varied clinical manifestations and, in some regions, the common occurrence of 
infectious colitis that can mimic UC. Prevalence and incidence in India have been estimated as 
44.3 per 100000 and 6.0 per 100000 population per year respectively10 
 
UC can occur at any age, although diagnosis before the age of five years or after 75 years is 
uncommon. The peak incidence of UC occurs in the second and third decades of life. Studies 
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have reported a second, smaller peak in the elderly, between the ages of 60 and 70 years. This 
second peak of disease incidence is less pronounced than that for Crohn's disease. Most studies 
have not shown any gender difference in the occurrence of UC, and a male-to-female ratio of 
nearly 1:1 applies to all age groups. The incidence and prevalence also varies according to 
ethnicity. The highest incidence is seen in the Jewish population.  
 
ETIOLOGY AND PATHOGENESIS 
The current understanding regarding the pathogenesis involves a complex interaction of three 
elements: genetic susceptibility, host immunity, and environmental factors. Loss of immune 
tolerance in a genetically predisposed individual leads to development of acute and chronic 
inflammation which causes mucosal damage. The candidates for specific inciting antigens 
causing the inflammatory response include pathogenic and commensal microorganisms, 
metabolic byproducts of these agents and their normal epithelial structures.  
GENETICS  
Family History  
Genetic factors predispose to UC, this is supported by familial incidence of UC of about 10% to 
20% of patients, who have at least one other affected family member11. As per evidence from 
European twin studies, around 6-16% of monozygotic twin pairs had concordant UC in 
comparison to 0-5% of dizygotic twin pairs12-14.  
Familial association is greater in persons of Jewish descent, a heritage known to have a higher 
incidence of IBD. The lifetime risk of developing disease is three-fold higher among first-degree 
relatives of Jewish patients compared with relatives of non-Jewish patients15. 
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Genetic Mutations  
The inheritance of UC is complex and polygenic. Linkage studies have suggested that there are 
susceptibility genes for UC on chromosomes 1, 2, 3, 5, 6, 7, 10, 12, and 1716-19.The IBD2 locus 
on chromosome 12 appears to have strong linkage demonstrated in studies involving large 
numbers of families with UC18. The C3435T polymorphism for the human multidrug resistance 1 
(MDR1) gene is linked to susceptibility for UC but not Crohn's disease20.  
A genome-wide association study showed strong association between the gene encoding IL-23R 
and both Crohn's disease and UC21. IL-23R plays a key role in the differentiation of a relatively 
newly discovered subset of T cells called Th17 cells. 
There also are genes that seem to influence disease. The best studied of these genes are the 
human leukocyte antigen (HLA) alleles. HLA-DR2 (DRB1*1502) appears to be involved in 
disease susceptibility in Japanese and Jewish populations. An association between severe disease 
and a rare allele of HLA-DR1 (DRB1*0103) has been reported. In some studies, the HLA-
DR3,DQ2 haplotype is associated with extensive colitis, particularly in women.  
 
ENVIRONMENTAL FACTORS  
It is now almost universally accepted that the pathogenesis of IBD is a result of continuous 
antigenic stimulation by commensal enteric bacteria, fungi, or viruses, leading to chronic 
inflammation in genetically predisposed hosts having defects in mucosal barrier function, 
microbial killing, or immunoregulation. No specific infective organism has been incriminated till 
date. 
The fact that both UC and Crohn’s disease preferentially occur in regions of the bowel that 
contain the highest concentration of bacteria, namely, the terminal ileum and the colon, where 
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bacterial concentrations approach 1012 organisms per gram of luminal contents, suggests that 
intestinal organisms could play a role. A diversion of  fecal stream in patients with inflammatory 
bowel disease can treat and even prevent disease, whereas reinfusion of ileostomy contents leads 
to new inflammatory changes within only one week22.  Data show that antibiotics are useful in 
the treatment or postsurgical prevention of Crohn's disease and pouchitis. Probiotics have been 
demonstrated to be effective in the primary and secondary prevention of pouchitis. The 
gnotobiotic (germ-free) rodent model reveal that without intestinal microflora, the rats remain 
healthy, but with intestinal colonization, they develop intestinal inflammation.35-38 Antibiotics 
and probiotics have been demonstrated to be useful in this model.39,40 
Recently, a lot of knowledge has been gained about the human gastrointestinal microbiome. 
There are at least 1800 genera and between 15,000 and 36,000 species of bacteria23-25; more than 
45,000 bacterial small-subunit (SSU) rRNA genes have been identified23-25.  Of the bacterial 
genes recognized till date, almost all (more than 98%) can be classified into four phyla25:  
- Firmicutes (64%); includes the family Lachnospiraceae (e.g., Clostridium groups XIVa 
and IV) and the subgroup Bacillus (e.g., Streptococcaceae and Lactobacillales) 
- Bacteroidetes (23%) 
-  Proteobacteria (8%); include the family Enterobacteriaceae (e.g., Escherichia coli) 
- Actinobacteria(3%) 
Four mechanisms have been hypothesized to explain how the normal intestinal microbiome 
might initiate or contribute to the development of the chronic inflammatory state26. First, 
microbes can trigger intestinal inflammation, either by adhering or invading intestinal epithelial 
cells, thereby initiating a cascade of  proinflammatory cytokine production.  
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Second, an alteration in the balance between protective and harmful intestinal bacteria, termed 
dysbiosis, can lead to disease. Comparisons of intestinal microbiome in IBD with that in healthy 
controls show reduction in biodiversity in the IBD populations by 30% to 50%. One study found 
that this reduction in biodiversity was due to decreased concentrations of Firmicutes (specifically 
Lachnospiraceae) by 300-fold and Bacteroides by 50-fold25. The loss of these organisms is 
important because they are known to produce short-chain fatty acids, such as butyrate, which 
nourish colonocytes. As a result of their decrease, the relative concentrations of Proteobacteria 
and Actinobacteria increase in IBD patients relative to controls, although quantitative PCR 
analysis showed that the absolute numbers of Enterobacteriaceae were not higher in IBD 
patients than in controls. Loss of protective bacteria, however, could set the stage for overgrowth 
of pathogenic bacteria.  
Third, genetic defects in host microbial killing or impaired mucosal barrier function could lead to 
immune hyper-responsiveness to intestinal bacteria, as the microbes have more exposure to 
epithelial cells and can trigger the production of high levels of proinflammatory cytokines. 
Fourth, genetic defects in host immunoregulation can lead to an abnormally high immune 
response to even nonpathogenic bacteria, by mechanisms of abnormal antigen processing or 
presentation, loss of tolerance, or overly aggressive T-cell responses.  
In addition to infectious agents, several other environmental factors have been proposed as 
contributing etiologic factors of UC. Smoking and previous appendectomy are believed to be 
protective in UC. 
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IMMUNE FACTORS  
Enteric immune response is incriminated to be an important factor in the pathogenesis of UC. 
Both humoral and cell-mediated responses are described to be abnormal.  
Humoral Immunity  
Tissue plasmacytosis is noted in the colon. Increased levels of IgG, predominantly IgG1 and IgG3 
subclasses is noted27,28.  Cross-reaction between microbial antigens and colonic epithelial 
epitopes may be an important event in pathogenesis. There is an increased association with other 
autoimmune disorders, namely thyroid disease, diabetes mellitus, and pernicious anemia.[53] The 
most well described intestinal auto-antigen is a 40-kDa epithelial antigen found in normal 
colonic epithelium29. The antibody response to this 40-kDa protein appears to be unique to UC. 
This autoantigen shares an epitope with antigens found in the skin, bile duct, eyes, and joints. 
This may explain the extraintestinal manifestations of UC. The exact significance of this 
autoantibody in UC, however, remains unclear presently. pANCA is another autoantibody, 
present in 60% to 85% of patients with UC30,31.  It is synthesized within the lamina propria and is 
of the IgG1 subclass. The current status of pANCA is that it has no pathogenic role in UC but 
that it might serve as a potential marker of susceptibility and genetically distinct subsets of UC. 
pANCA may be associated with a more-aggressive disease course32 and with the development of 
pouchitis after ileal pouch-anal anastomosis (IPAA) in patients with UC33,34. pANCA 
seroreactivity is associated with a predominant colonic involvement in Crohn’s disease35. 
Some antibodies to bacterial antigens have been identified in UC - anti-CBir1 and anti-OmpC. 
Anti-Cbir1 is an antibody to flagellin from Clostridium species; found in about 6% of UC 
patients36 and appears to be related with the development of pouchitis37. Anti-CBir1 also is found 
in 50% of patients with Crohn's disease, in which it is associated with more complicated 
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disease36. Anti-OmpC (outer membrane porin C of E. coli) is seen more often in UC patients 
who have a mixed family history of Crohn's disease and UC rather than those with a family 
history of only UC38. 
Cellular Immunity  
Immune dysregulation in UC affects both innate and adaptive components of cell-mediated 
immunity. The innate immune system provides the first line of non-specific defence against all 
foreign antigens. Pattern-recognition receptors (PRRs) are present on cell membranes, which 
comprise of  the 11 Toll-like receptors (TLRs) and 23 nucleotide-binding oligomerization 
domain (NOD)-like receptors (NLRs) identified till date. 
Antigen binding at the TLRs and NLRs results in a cascade of events, leading to a final common 
pathway of nuclear factor-κB (NF-κB) activation, which enhances the transcription of genes 
encoding for various proinflammatory cytokines (including TNF, IL-1, IL-6, and IL-8), 
chemokines, adhesion molecules, and costimulatory molecules. Activation of NF-κB also 
hastens the maturation of dendritic cells, that are involved in antigen presentation. Defects in any 
part of the innate immunity leads to abnormal bacterial processing and possibly IBD39. 
The adaptive immune system, comprising T cells and B cells, is specific. Lymphocytes are 
classified as per their locations in the mucosa: lamina propria lymphocytes and intraepithelial 
lymphocytes (IELs). Lamina propria lymphocytes express, α4β7, a surface adhesion molecule 
that provides a homing signal for peripheral immune cells to the mucosal sites40.  Mucosal T 
cells within the lamina propria and epithelium, as well as peripheral blood T cells, display 
activation markers, suggesting an activated memory phenotype41. There is evidence that the T-
cell receptor repertoire is altered in active IBD42. 
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Epithelial Cells  
Intestinal epithelial cells not only serve as a barrier, but also play a role in enteric immunity. 
Colonocytes express class II major histocompatibility complex (MHC) antigens and function as 
antigen-presenting cells43. They are functionally active and express cytokine receptors, secrete 
various cytokines and chemokines, and express leukocyte adhesion molecules44-47.  
Patients with UC have an increased turnover rate of colonic epithelium48 and abnormalities of 
epithelial cells like reduced metabolism of short-chain fatty acids, especially butyrate, abnormal 
membrane permeability49, and altered composition of glycoprotein mucus produced by the 
colonic epithelium50. The mucus layer in UC is thinner than normal51. These abnormalities can 
lead to increased numbers of adherent bacteria, in both the mucus layer and even at the epithelial 
surface, in patients with UC52-54. The role of epithelial cells in the pathogenesis of IBD is 
vindicated further by animal models of colitis produced by disruption of colonic epithelium55. 
 
Consequences of Immune Activation  
CD4+ T cells are classified into three major immune phenotypes: T helper 1 (Th1), T helper 2 
(Th2), and a newly recognized subset called T helper 17 (Th17).  
The Th1 response, initiated by IL-12 due to exposure to infectious agents  is characterized by 
cell-mediated immunity and is associated with the production of interleukin (IL)-2 and interferon 
(IFN)-γ. The Th2 response is characterized by the production of cytokines IL-4, IL-5, IL-10, and 
IL-13, which amplify the humoral immune response. Th1 and Th2 subsets reciprocally down-
regulate each other through cytokine production56. Th1 and Th2 pathways can be regulated by 
unique regulatory T cell (Treg) subsets that produce IL-10 and transforming growth factor 
(TGF)-β and down-regulate inflammation57. 
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An oversimplification of  adaptive immunity in IBD would be to say that Crohn's disease is 
mediated by Th1 cells whereas UC is mediated by Th2 cells; the true story is much more 
complex. Macrophages in the inflamed colon in UC produce IL-1β, TNF, and IL-6, whereas 
lamina propria T cells probably produce IL-2 and IFN-γ. Presentation of antigen to CD4+ 
lymphocytes by colonic epithelial cells that express HLA class II antigens further enhances this 
immune response43. A specialized type of T cell, the natural killer (NK) T cell, seems to mediate 
the Th2 response in UC58,59. These NK T cells, unlike classical NK T cells do not express the 
typical NK T-cell receptors and secrete large amounts of IL-5 and IL-13, which are cytotoxic for 
intestinal epithelial cells.  
A novel T-cell–mediated inflammatory pathway, the Th 17 pathway has been recently 
discovered. Th17 cells produce a variety of cytokines, mainly IL-6 and IL-17. IL-17 is a potent 
proinflammatory cytokine that facilitates T-cell activation and stimulates an array of cells, 
including fibroblasts, macrophages, epithelial cells, and endothelial cells, to produce a variety of 
proinflammatory cytokines like IL-1, IL-6, TNF-α, and chemokines60. Th17 lineage is inhibited 
by Th1 and Th2 cells but is promoted by IL-6, TGF-β, IL-21, and IL-23R61. IL-23R, which is 
highly expressed by activated Th17 cells, also is expressed by NK cells, NK T cells, other CD4+ 
T cells, and CD8+ T cells19. The interaction of IL-23 with its receptor has been shown to have a 
pivotal role in the development of inflammation in various mouse models of colitis62,63. 
Antibodies to IL-23 could be a potential therapeutic target in the future.  
 
PSYCHOGENIC FACTORS  
There is evidence that psychosocial stress increases the risk of relapse in patients with quiescent 
UC64,65. 
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Fig 1: Immune pathways in ulcerative colitis.(Courtesy: www.biolegend.com) 
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PATHOLOGY 
At initial presentation, approximately 45% have disease limited to the rectosigmoid, 35% have 
disease extending beyond the sigmoid but not involving the entire colon, and 20% of patients 
have pancolitis66. Typically, the disease is most severe distally and progressively less severe 
more proximally. Continuous and symmetrical involvement is the hallmark of UC. There is a 
sharp transition between diseased and uninvolved segments of the colon. 
In two conditions, skip lesions can occur. First, when the patient is treated with topical enema 
leading to mucosal healing in the rectum and distal colon. Second, 75% of the patients with left 
sided UC have peri-appendiceal inflammation and patchy inflammation in the caecum. 
Macroscopically, the  mucosa appears hyperemic, edematous and granular in early disease, 
which progresses to visible punctuate ulcers with hemorrhagic mucosa. Ulcers enlarge and 
extend upto the lamina propria. Epithelial regeneration with recurrent attacks leads to a 
pseudopolyp like appearance. With long standing disease the colonic mucosa becomes atrophic 
and featureless.  
Microscopically, the early stage of UC shows edema of the lamina propria with congestion of 
capillaries and venules, often with extravasation of red blood cells. Neutrophilic infiltration of 
colonic crypts causes cryptitis and ultimately to crypt abscesses with neutrophilic accumulations 
in crypt lumens. Inflammation is typically confined to mucosa and usually do not extend beyond 
the luminal aspect of muscularis mucosa. The classic histologic description of chronic quiescent 
UC is crypt architectural distortion or actual dropout of glands. Architectural changes include 
branching or bifid glands, wide separation among glands, and shortened glands that do not 
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extend down to the muscularis mucosa. Paneth cell metaplasia (Paneth cells located distal to the 
hepatic flexure, where they normally are absent) is another feature typical of UC. 
CLINICAL FEATURES 
Symptoms can range from diarrhea, rectal bleeding, passage of mucus, tenesmus, urgency, and 
abdominal pain. In severe cases, fever and weight loss may be prominent. The symptomatology 
differs according to the extent of disease67. Patients with proctitis predominantly present with 
tenesmus, urgency, mucus, and bleeding, whereas patients with extensive colitis present with 
more diarrhea, weight loss, fever, clinically significant blood loss, and abdominal pain. Up to 
30% of patients with proctitis or proctosigmoiditis complain of constipation and hard stools68. 
Fever and tachycardia are associated with severe disease. Abdomen is usually soft with mild 
tenderness over the diseased segment. 
DIAGNOSIS 
Anemia, hypoproteinemia and elevation of inflammatory markers like ESR and CRP may be  
present with severe disease.  A stool examination for parasites, faeces culture and toxin for 
Clostridium difficile is important to rule out infectious mimics of UC. Diagnosis is confirmed by 
colonoscopy and biopsy.  
ASSESSMENT OF SEVERITY 
Two assessment scores are popularly used in UC -  Truelove and Witts classification and the 
Ulcerative Colitis Disease Activity Index (UCDAI). There are in addition, endoscopic and 
histologic scales in grading colitis. 
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Truelove and Witts Classification of the Severity of Ulcerative Colitis69 
Mild 
    <4 stools/day, without or with only small amounts of blood
    No fever 
    No tachycardia 
    Mild anemia 
    ESR < 30 mm/hr 
 
Moderate 
Intermediate between mild and severe 
Severe 
    >6 stools/day, with blood 
    Fever > 37.5?C 
    Heart rate > 90 beats/min 
    Anemia with hemoglobin level < 75% of normal
    ESR > 30 mm/hr 
 
 
 
 
Endoscopic and Histologic Assessment of Disease Activity in Ulcerative Colitis70,71 
SCORE CRITERIA 
Endoscopic Assessment 
0 Normal mucosa 
1 Loss of vascular pattern 
2 Granular, nonfriable mucosa 
3 Friability on rubbing 
4 Spontaneous bleeding, ulceration 
Histologic Assessment 
0 Normal 
1 
No significant inflammation: Possibly architectural changes of chronic disease and 
small foci of lymphocytes but no acute inflammation, crypt abscesses, or epithelial 
destruction  
2 Mild to moderate inflammation: Edema, vascularity, increased acute and chronic inflammatory cells but intact epithelium 
3 Severe inflammation: Heavy infiltrate of acute and chronic inflammatory cells, crypt abscesses, ulceration of surface epithelium, purulent exudate  
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Ulcerative Colitis Disease Activity Index72 
SCORE CRITERIA 
Stool Frequency 
0 Normal 
1 1-2 stools/day > normal 
2 3-4 stools/day > normal 
3 >4 stools/day > normal 
Rectal Bleeding 
0 None 
1 Streaks of blood 
2 Obvious blood 
3 Mostly blood 
Mucosal Appearance 
0 Normal 
1 Mild friability 
2 Moderate friability 
3 Exudation, spontaneous bleeding
Physician Global Assessment 
0 Normal 
1 Mild 
2 Moderate 
3 Severe 
 
* Sutherland index: Range, 0-12 
None of these disease activity instruments has ever been formally validated. Generally,  a patient 
is considered to be in remission if the UCDAI score is 2 or less and to have severe disease if the 
score is greater than 10. A decrease in three points from the patient’s initial baseline score 
reflects a clinical  response. An index very similar to the UCDAI that has been used extensively 
in recent randomized, controlled trials (RCTs) is the Mayo score, which incorporates the same 
four components as the UCDAI 
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TREATMENT 
Treatment depends on various factors 
 
 
 
 
 
 
 
 
Induction Therapy for Ulcerative Colitis Based on Disease Severity 
Mild Disease 
   
 5-Aminosalicylates  
    Topical (distal colitis) 
    Oral (distal/extensive colitis) 
    Combination 
 
 
Moderate Disease 
   
 5-Aminosalicylates  
    Topical (distal colitis) 
    Oral (distal/extensive colitis) 
    Combination 
 
   
 Glucocorticoids  
    Topical (distal colitis) 
    Oral (distal/extensive colitis) 
    Combination 
 
    Azathioprine or 6-mercaptopurine 
 
Severe Disease 
    IV glucocorticoids 
    IV cyclosporine 
    IV infliximab 
 
MEDICATION CHOICE
SEVERITY OF DISEASE 
Mild, moderate or 
severe 
DISEASE DISTRIBUTION
Distal or Extensive 
PRIOR THERAPY 
Response, side effects, 
compliance 
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EXTRAINTESTINAL MANIFESTATIONS 
Common Extraintestinal Manifestations of Ulcerative Colitis 
Cutaneous/Oral 
    Angular stomatitis 
    Aphthous stomatitis 
    Erythema nodosum 
    Oral ulcerations 
    Psoriasis 
    Pyoderma gangrenosum 
    Pyostomatitis vegetans 
    Sweet's syndrome (acute febrile neutrophilic dermatosis)
 
Ophthalmologic 
    Conjunctivitis 
    Episcleritis 
    Retinal vascular disease 
    Scleritis 
    Uveitis, iritis 
 
Musculoskeletal 
    Ankylosing spondylitis 
    Osteomalacia 
    Osteonecrosis 
    Osteopenia 
    Osteoporosis 
    Peripheral arthropathy 
   Sacroiliitis 
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Hepatobiliary 
    Autoimmune hepatitis 
    Cholangiocarcinoma 
    Pericholangitis 
    Primary sclerosing cholangitis 
    Hepatic steatosis 
 
Hematologic 
    Anemia of chronic disease 
    Autoimmune hemolytic anemia 
    Hypercoagulable state 
    Iron deficiency anemia 
    Leukocytosis or thrombocytosis 
    Leukopenia or thrombocytopenia
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INTERACTIONS OF PARASITES, CMV AND CLOSTRIDIUM DIFFICILE WITH UC 
Evidence in the literature do not point to any specific infection as a causative mechanism in  
IBD, but indicate that gut pathogens could cause trigger the onset of IBD and are associated with 
aggravation of quiescent disease. Though these infections are self limited, they initiate an 
inflammatory cascade, which lead to a series of events leading to chronic disease in a genetically 
susceptible host (‘hit-and-run’ hypothesis). Epidemiological and microbiologic studies suggest 
that enteropathogenic microorganisms play an important role in the clinical initiation and 
relapses of IBD. Thus, for optimal medical treatment, microbiologic screening is helpful in 
patients with flares of IBD. 
A recent report from AIIMS found that 12% of patients with active UC had parasites, 8% had 
CMV and 10% had HSV infection73. The clinical presentation of an acute episode in a majority 
of UC patients is indistinguishable from enteric infection. Patients with ulcerative colitis often 
have intermittent flares alternating with periods of quiescent disease. Intestinal infections may be 
responsible for flares in some of these patients. Of the intestinal parasites, infection with 
Entamoeba histolytica and Strongyloides stercoralis is likely to cause flares in ulcerative colitis. 
Less commonly recognized are infection with cytomegalovirus and Clostridium difficile.  In a 
study from Chandigarh, C. difficile toxin was detected in the stool of 13% of patients with UC74. 
In an earlier study from the same centre, 32% of active UC patients had parasitic or bacterial 
pathogens, compared to 4% of inactive UC patients75. 
Treatment of ulcerative colitis flare is essentially immunosuppressive. It  is very important to 
recognize an underlying enteropathogen, prior to hiking the immunosuppression regime of the 
patient. Prompt diagnosis and treatment of  infection can prevent unnecessary use of steroids and 
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immunosuppressive therapy. Enteric infections are common in tropical countries like India. 
Thus, there is still the chance that enteric pathogens could alter the natural history of UC. 
A large population based cohort study showed that the use of biologic agents does not seem to 
increase the risk for Clostridium difficile infection(CDI)76. Recently published single-center 
studies and US inpatient database studies reported increasing rates of CDI among IBD patients 
and their role in an increased rate of hospitalizations and mortality77-80. The risk of CDI in IBD 
patients appears to persist even after colectomy. CDI can involve the small bowel81. CDI has also 
been reported in UC patients with restorative proctocolectomy with ileal pouch-anal anastomosis 
(IPAA)82,83. 
Short and long-term outcomes with Clostridium difficile infection and 
inflammatory bowel disease84 
 
Short-term outcomes 
Toxic megacolon 
Colonic perforation 
Peritonitis with sepsis 
? Increased hospitalization duration and costs 
Colectomy rates highly variable 
 
Long-term outcomes 
Increased UC related hospitalization and emergency room visits 
? Escalation of medical treatment 
Increased rate of colectomy 
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Table 1:  Differentiating Clostridium difficile infection and inflammatory bowel disease84 
Features Isolated CDI CDI and IBD 
Setting  Often hospital acquired Often community acquired 
Risk factors • Antibiotic exposure prior to 
infection common 
• Immunomodulator & 
corticosteroid use 
• Increasing age 
• Many patients lack history of antibiotic 
exposure 
• Immunomodulator and corticosteroid 
use playing even a greater role 
• Increasing age 
• Risk greater with UC than with CD, 
greater with colonic involvement than 
with small bowel  
Clinical 
features 
Watery diarrhea Bloody or mucoid diarrhea 
Short term 
outcome 
Complications include toxic 
megacolon, perforation, 
peritonitis with sepsis 
Similar to patients without IBD 
Hospital costs and length of stay variable 
in studies 
Increased mortality in some studies  
Risk of colectomy unclear 
Long term 
outcome 
- Unclear; increase in hospitalization, 
increased medication usage and colectomy 
rates noted in retrospective studies  
Diagnosis ELISA testing for stool testing ELISA may be less sensitive 
Endoscopy Pseudomembranes seen Pseudomembranes rare 
Treatment Metronidazole for mild to 
moderate disease 
Vancomycin for severe disease 
?Vancomycin for any hospitalized patient 
Recurrence 20% after 1st episode Highly variable 10-58%, may be higher  
Extra-colonic 
involvement 
Small bowel can be affected Most cases of IBD have small bowel 
involvement; pouchitis can also occur 
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Although a variety of tests are available for the diagnosis of Clostridium difficile infection, 
ELISA for stool toxin is the most commonly performed test. ELISA is relatively inexpensive, 
easily available and technically less cumbersome than other techniques. It is based on the 
detection of toxin A and/or B in the stool using either a monoclonal antibody or a polyclonal 
antiserum that recognizes the specific toxin. Results are available within 2-6 hours. Most 
ELISAs for detection of both toxins A and B in stool have a sensitivity of 70-90% compared to 
culture of Clostridium difficile. Upto 30% of tests may be falsely negative, considering tissue 
cytotoxicity assay or culture as gold standard85,86. Specificity is very high (99%)86,87. Lower 
sensitivity of ELISA test can be improved by performing it on 2 or 3 consecutive specimens 
rather than on 1 specimen, which increases the diagnostic yield by 5%-10%88. The diagnostic 
yield of ELISA testing may be much lower in IBD patients. Four sequential stool samples were 
shown to increase the diagnostic yield to 92%89. 
Cell cytotoxicity assay is the current gold standard test for diagnosis of CDI. It detects as low as 
10 picograms of toxin and is the most sensitive test for detection of toxin B90-93. It is based on the 
principle that the toxins in the stool exert a cytopathic effect characterized by cell rounding 
which can be demonstrated in tissue culture. The test is highly sensitive (94%-100%) and 
specific (99%). Disadvantages are its relatively high technical expertise and the 24-48 h needed 
to complete the assay94. Stool culture is seldom used for routine diagnosis because of labor 
intensiveness, long turnaround time (24-48 h) and a low specificity. culture permits molecular 
typing of the organisms, it is essential for monitoring molecular epidemiology and antibiotic 
susceptibility90. 
Polymerase chain reaction (PCR) based primers for the detection of genes for toxins A are 
available and this test is highly sensitive and specific for the diagnosis of CDI95,96. Culture of the 
25 
 
organisms may be required for PCR, which makes the process more technically demanding and 
challenging. A study based on the nested PCR assay reported a 99% concordance with the 
cytotoxicity assay and a sensitivity of 96.3% and a specificity of 100%96. 
In patients with IBD who present with worsening symptoms, CDI should be thought of and ruled 
out. In patients with a suspected diagnosis of CDI in IBD, stool studies for CDI are sent and 
empiric treatment is started. ELISA is the most commonly used method of diagnosis of CDI. 
Treatment may be started awaiting results of assay (vancomycin 125 mg orally every 6 h with 
continuation of their previous mmunosuppressive therapy). No new immunomodulators or 
escalation of immunosuppressive medications should be done in patients with suspected CDI in 
IBD unless CDI is ruled out with serial stool studies (at least 3-4). The duration of antibiotic use 
is 14 days. Routine endoscopy is not necessary as the yield of pseudomembranes is very low 
unless an alternative diagnosis such as cytomegalovirus infection is being entertained. Patients 
should be serially followed to study the impact of CDI on the short term and long term outcome 
of IBD. 
Cytomegalovirus (CMV) is a member of the Herpesviradae family. It is transmitted through 
close personal contact with body fluids, including saliva, urine, blood, breast milk, semen, and 
transplanted organ tissue97. CMV infection is ubiquitous in developed nations, with laboratory 
evidence of prior infection in 40%–70% of the general adult population98,99. 
Immunocompromised patients may have severe end-organ involvement as a presentation of 
primary acute CMV infection97,100. Conversely, immunocompetent individuals with primary 
CMV infection are usually asymptomatic. In this setting, primary CMV infection is generally 
self-limited, and resolves to a state of lifelong latency. In the latent phase, the viral genome 
exists in an episomal circular form and does not replicate101. Latent infection does not increase 
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morbidity or mortality. Immunosuppression can reactivate CMV replication and cause its 
migration to inflammed tissue to further propagate infection102,103. Ample evidence in literature 
suggests that there is increased colonic CMV reactivation in ulcerative colitis patients98,100, 104-107. 
There are conflicting reports on whether or not CMV reactivation is associated to 
immunosuppression (steroids, cyclosporine or biologicals). Steroid refractory disease has also 
been incriminated as one of the risk factors for CMV reactivation104,105. 
Accurate and efficient diagnosis of active CMV reinfection remains a challenge. CMV-specific 
testing has been unreliable in the diagnosis of  active CMV colitis. CMV serology, antigen 
testing, and DNA testing, though useful in identifying prior exposure history, can be difficult to 
interpret in the setting of active infection and results correlate poorly with active disease113,114.   
Table 2: Summary of diagnostic techniques and its characteristics for CMV infection115-123 
Diagnostic test Pros Cons Sensitiv
-ity(%) 
Specifici
-ty(%) 
Serum serology Can able to detect prior 
infection 
Unable to detect active 
colitis 
98-100 96-99 
Antigen testing Reasonable sensitivity 
and specificity for active 
disease 
Semi-quantitative, 
results subjective 
60-100 83-100 
Culture High specificity Long incubation; poor 
sensitivity 
45-78 89-100 
DNA PCR 
(serum) 
High negative predictive 
value; may correlate with 
active disease 
Different assays and 
quantitation methods; 
low specificity 
65-100 40-92 
Histology(H & E) Inexpensive stain Poor sensitivity 10-87 92-100 
Immunohistology Improves sensitivity over 
H & E stain 
Expensive stain 78-93 92-100 
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Histological demonstration of classical cytopathic changes is the current gold standard for 
diagnosis of CMV reactivation.  
Many studies have shown the CMV reactivation as a risk factor for increased morbidity and 
mortality.. In a prospective observational study involving 114 patients, it was found that among 
steroid refractory UC, 3 of 6 (50%) patients with evidence of CMV reactivation proceeded to 
colectomy, compared to 2 of 13 (15%) steroid-refractory patients without CMV104.  In another 
Indian study of 63 patients, 61 of which were UC patients, 4 of 10 (40%) patients with CMV 
required surgical intervention compared to 4 of 53 (7%) UC patients without CMV. Furthermore, 
3 of 10 (30%) UC patients with CMV had fatal outcome, compared to 0 of 53 (0%) UC patients 
without CMV124. Early detection of CMV reactivation in UC patients enables prompt therapeutic 
intervention with IV ganciclovir or forscarnet, which has been shown to improve clinical 
outcomes. However, there are investigators who believe that CMV could just be an innocent 
bystander and has no role in acute exacerbation of UC. 
Despite the burning debate about the non-pathogenicity of CMV reactivation, current literature 
indicates that UC patients are at higher risk for CMV reactivation, and that the failure to 
appropriately diagnose and treat these patients may lead to significant morbidity and mortality. 
This higher risk is likely multifactorial involving both iatrogenic immunosuppression and 
underlying factors such as severe inflammation, malnutrition and inherent immunogenicity. 
However, the mechanisms behind these factors have not been fully understood. Patients 
presenting with severe and/or refractory UC, especially patients with significant steroid use 
history should be evaluated for possible CMV reactivation as a possible contributor to their 
symptoms. 
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Figure 3: Common parasite co-infections in Ulcerative Colitis  
 
30 
 
METHODS 
The study was a prospective cross-sectional observational study. The study protocol and consent 
form (Appendix) were approved by the Institutional Review Board (IRB) 
Setting:  
Department of Gastrointestinal Sciences, Christian Medical College, Vellore.  
Period of recruitment:  
January 2009 to January 2011 
Participants:  
Inclusion Criteria  
- All cases of ulcerative colitis who were seen as indoor or as indoor patients were 
included in the study. The diagnosis of ulcerative colitis was established on the basis of 
Asian consensus criteria (Ooi et al125). The diagnosis of confirmed cases of ulcerative 
colitis was based on detailed clinical history, physical examination, typical colonoscopic 
findings and histology. Typical history included bleeding per rectum with mucus or 
bloody diarrhea presently or in the past. Colonoscopy appearance typical of ulcerative 
colitis was considered to be symmetrical and continuous inflammation starting from the 
rectum, extending proximally without interruption with features of loss of normal 
vascular pattern, erythema and edema of mucosa with or without granularity, friability 
with presence of yellow brown mucopurulent exudates associated with mucosal 
ulceration(which can be punctate, annular, linear or serpigenous), with or without the 
presence of pseudopolyps. Histology showing cryptitis or crypt abscesses and absence of 
granulomas was considered typical. Histologically the disease was graded as quiescent, 
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mild, moderate and severe depending on the activity. Quiescent colitis was characterized 
by presence of architectural alterations with or without the presence fibrosis with no 
features of neutrophils infiltration, no edema no ulcers. The disease was graded 
histologically as mild, moderate or severe according to the degree of neutrophil 
infiltration of the crypts and depth of mucosal infiltration, amount of mucin depletion and 
the amount of edema and congestion with or without presence of the ulcers.  
Exclusion criteria 
- Failure to provide consent 
- Alternative diagnosis established after initial evaluation 
Variables: 
Ulcerative colitis – disease activity graded as mild, moderate or severe as per Truelove Witts 
criteria 
 Measurements:  
- Usual indicated clinical and laboratory evaluation including CBC, ESR, CRP, Ca, P, LFT 
- Ileo-Colonoscopy and segmental biopsy 
- 3 fresh samples of stool were analyzed for parasites (including special stains) 
- Stool ELISA for Clostridium difficile toxin 
STUDY PROTOCOL 
Consecutive patients were included in the study. Patients were formally interviewed and 
examined by the principal investigator. The patient was explained about the disease and was 
advised to undergo colonoscopy with segmental biopsies which is part of the current standard of 
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care. The clinical profile was scored according to disease activity scale – Truelove-Witts. Stool 
samples to look for parasites were collected on at least three consecutive days. One stool sample 
was analysed for ELISA for Clostridium difficile toxin. Segmental colorectal biopsies were 
looked at for evidence of parasites and for changes suggestive of CMV infection (classic owl-eye 
inclusion bodies).  
The methods followed for stool examination for parasites are detailed below: 
STOOL ROUTINE PARASITES: 
Wet preparation – A drop of normal saline was placed on the slide. A uniform stool 
suspension was made and a coverslip was placed gently without creating any air bubbles. 
The thickness of the preparation was such that printed material could be read through it. 
The stool was examined under the microscope so as to cover all areas of the slide.  
Iodine preparation – A drop of iodine was placed on the slide. A uniform stool 
suspension was made and a coverslip gently placed over it. The slide was systematically 
scanned using the 10x and 40x objectives of the microscope.  
In a wet preparation, motile trophozoites, larvae, cysts and ova can be identified. In an 
iodine preparation, internal nuclear characters of protozoan cysts can be seen. 
Formol ether concentration technique was used for analysing the stool sediment after 
concentration. The following was the method used. The stool was mixed well in the 
container using a clean stick. Approximately 1 gram of faeces was selected to include 
external, internal and mucus portions of the sample. The sample was placed in a 
centrifuge tube, containing 7 ml of 10 % formalin. The faeces was emulsified in formalin. 
Following this, the emulsified solution was transferred to another centrifuge tube and 3 
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ml of ether was added. This was mixed well on a vortex mixer for 15 seconds or by hand 
for 1 minute. This solution was centrifuged at 3000 rpm for 1 minute. The fat plug of 
debris from top of the tube was cleared by ringing the sides of the tube with a stick. The 
top layer of supernatant was removed by quickly inverting the tube. A few drops of 10% 
formalin was added to the sediment and mixed well.  A slide for examination was made 
from the sediment, using saline and iodine preparations. 10x and 40x objectives were 
used to examine the whole smear for ova and cysts.The following special stains were 
done on the stool sample on the concentration sediment  
            1. Modified acid fast stain  
            2. Modified trichrome stain 
            3. Rapid  Field’s stain  
Modified acid fast stain: The stool smear was allowed to air dry, following which it was 
fixed in methanol for 3 minutes. The smear was stained with carbol fuchsin for 15 - 20 
minutes. Following this, it was rinsed thoroughly in tap water. The stain was decolorized 
with 1% acid alcohol for 15 – 20 seconds. The smear was again rinsed with tap water and 
counterstained with methylene blue for 30 -60 seconds. After rinsing thoroughly in tap 
water, the smear was examined using the 100x oil objective.  The modified acid fast stain 
is useful to identify opportunistic parasites, such as Cryptosporidium, Cyclospora and 
Isospora. Oocysts of Cryptosporidium stain an intense red colour and most will contain 
several prominent black granules against the blue background. 
Modified trichrome stain: The smear was fixed with methanol for 5 minutes. The smear 
was stained with chromotrope stain for 60 minutes at room temperature or for 10 minutes 
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at 50°C. The slide was rinsed thoroughly in tap water. Then, the smear was destained in 
acid alcohol for only 1-2 seconds. The slide was then rinsed in 95% ethanol by dipping it 
in for 1-2 seconds. Then it was dehydrated with 95% ethanol for 5 minutes and then in 
100% ethanol for another 5 minutes. The slide was dipped in xylene for a few seconds. 
The slide was dried and then examined under the 100x oil objective to identify 
Microsporidia (belonging mainly to the genera Enterocytozoon or Encephalitozoon). 
Microsporidial spores stain a pinkish – red color; 1.5 – 2 µm with a clear vacuole and 
membrane fold.  
Rapid Field’s stain: 
A thin film of faeces was made on the microscopic slide and was allowed to air dry. The 
slide was fixed with methanol for 1 minute. The slide was flooded with 1 ml of Field’s 
stain B (diluted 1: 4 with distilled water). An equal volume of undiluted Field’s stain A 
was added and mixed well. The slide was allowed to stand for a minute. Then it was 
rinsed well in tap water and drain dried. The smear was examined under the 100x oil 
objective of the microscope. The Rapid Field’s stain is useful for detection of 
trophozoites and cysts of Giardia, Blastocystis hominis and Dientamoeba fragilis 
Flagella, cilia and nuclei stain red. Cytoplasm stains bluish-grey. 
Stool for Clostridium difficile ELISA:  
The ELISA kit used was the ProSpecT™ Microplate assay (Thermo Fisher Scientific 
Remel Products, Lenexa, Kansas, USA). A microplate ELISA assay, it detected both C. 
difficile Toxin A and B. The results were read by a microplate reader. An optical density 
> 0.080 was considered as positive. Compared to tissue culture cytotoxicity assay, 
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specificity was 96.2% and sensitivity was 90.3%. The analytical sensitivity for toxin A 
and toxin B was respectively > 0.20 ng/ml and  > 0.61 ng/ml.   
COLONOSCOPY AND SEGMENTAL BIOPSY:  
Olympus CF V70L or 150L was used for colonoscopy. After consent and explanation of 
procedure, the colonoscope was inserted upto the ileum. A withdrawal time of 7 minutes 
was minimum for a proper evaluation of the entire colon. Segmental biopsies were 
obtained from ileum, caecum, ascending, transverse colon, descending, sigmoid colon 
and rectum were collected in separate bottles. 
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SAMPLE SIZE CALCULATION: 
We assumed that 55 % of our patients would have moderate to severe UC. We further assumed 
that the risk of having one of these organisms(bacteria, virus or parasites) would be 0.25 in the 
severe group and 0.05 in the mild group. We analysed and found that we needed 50 patients in 
the moderate-severe UC group and 37 patients in the mild group to be able to reject the null 
hypothesis that infection with pathogens is not associated with disease activity with 
probability(study power) 0.8 and a type I error probability of 0.05. 
 
STATISTICAL METHODS: 
SPSS version 15.0 was used to analyse data. Frequencies of variables were calculated. Mean and 
range were calculated for continuous data. Chi-square test (Fisher exact test) was used to find out 
correlation between UC activity and presence of parasites, CD toxin or CMV positivity. 
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Figure 6: Religion distribution (n=87): 
 
Age of onset of symptoms: 
Mean age of onset of symptoms of ulcerative colitis was 35.2 + 12.6 years (Range: 13-67) 
Table 3: Age distribution at onset of symptoms  
Age range Number of patients Percentage(%) 
11-20 12 13.8 
21-30 25 28.7 
31-40 23 26.4 
41-50 14 16.1 
51-60 11 12.6 
61-70 2 2.4 
Total 87 100% 
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Symptoms: 
The following were the symptoms of ulcerative colitis noted in our patients. 
Table 4: Symptoms in ulcerative colitis patients 
Symptoms Number of patients Percentage 
Diarrhea 82 94.3 
Bloody stools 83 95.4 
Abdominal pain 41 47.1 
Urgency 74 85.1 
Incontinence 48 55.2 
Tiredness 71 81.6 
Fever 16 18.4 
Weight loss >5 kg 64 73.6 
Joint involvement 36 41.4 
Eye involvement 1 2.3 
Skin involvement 0 0 
 
Most common symptoms in ulcerative colitis noted in our study were bloody stools (95.4%) and 
diarrhea (94.3%). Urgency and incontinence were seen in 85.1% and 55.2% of patients 
respectively. Arthritis was noted in 41.4% of our patients. Only one patient(2.3%) had eye 
involvement in the form of iritis.  
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Past history: 
Table 5: Past and family history: (n=87) 
 Number Percentage 
Diabetes mellitus 10 11.5 
Hypertension 11 12.6 
Tuberculosis 5 5.7 
Appendicectomy 5 5.7 
Family history 5 5.7 
 
10(11.5%) of our patients had diabetes mellitus, 11(12.6%) of our patients had hypertension. 
History of appendicectomy was present in 5(5.7%).  
5.7 % had a first or second degree relative having ulcerative colitis. 
Personal history: 
Table 6: Personal History: 
 Number of patients Percentage 
Smoking 11 12.6 
Tobacco chewing 19 21.8 
Alcohol 2 2.2 
Non vegetarian diet 80 92 
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11 (12.6%) of our patients were smokers. 19(21.8%) had a habit of tobacco chewing. Majority of 
our patients were non-vegetarian (92%). 
Treatment history: 
Table 7: Treatment history 
 Number of patients Percentage 
Present 5-ASA use 64 73.6 
Past 5-ASA use 62 71.3 
Oral steroid use 36 41.4 
Rectal steroid use 19 21.8 
IV steroid use 2 2.3 
Azathioprine use 15 17.2 
 
Most of our patients were on treatment when they were enrolled for the study. The most 
commonly used agent was 5-ASA (aminosalicylic acid) (73.6%). Oral steroids were being used 
by 41.4% of our patients. 17.2% of our patients were on azathioprine.  
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Laboratory parameters: 
Baseline laboratory parameters were as under 
Table 8: Lab parameters: 
 Mean + SD (Range) 
Haemoglobin (g%) 11.7 + 2.4 (5.8-19) 
ESR 41.2 + 29.2 (2-125) 
Albumin(g%) 4 + 0.9 (0.9-5.2) 
 
Biopsy activity:  
Majority of patients (58.6%) had moderate inflammation UC on biopsy, 11.6% had severe and 
29.8% had mild activity.  
Table 9: Biopsy activity:  
 Number of patients Percentage 
Mild 26 29.8 
Moderate 51 58.6 
Severe 10 11.6 
 
Pathogens detected:  
Pathogens (either of parasites, cytomegalovirus or Clostridium difficile toxin) were found in 
17.2%  of patients. 10(11.5%) of patients had a parasitic infestation. 
45 
 
Table 10: Pathogens detected : 
 Number Percentage 
Parasites 10 11.5 
Cytomegalovirus 2 2.3 
Clostridium difficile toxin 3 3.4 
 
Cytopathic changes on colonic biopsy were found in 2 out of 87(2.3%) patients. Both had severe 
UC and had to be hospitalized for treatment. In both patients, the colonic mucosal biopsy PCR as 
well as blood mononuclear cell PCR were positive for CMV. One of them responded only 
partially to ganciclovir and subsequently required subtotal colectomy while the other improved 
with ganciclovir and medical therapy for ulcerative colitis.  
Clostridium difficile toxin in stool was detected in 3 out of 87(3.4%) patients. All the three had 
severe UC as per Truelove-Witts criteria. Prior antibiotic use was present in two out of three 
patients 
Parasites:  
Table 11: Parasites: (n=10) 
Parasite Number  
Giardia cysts 5 
Strongyloides larva 3 
Hookworm ova 2 
Hymenolepis nana ova 1 
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Note: One patient had infection with both strongyloides and hookworm. 
The most common parasite noted was giardia (5 patients), followed by strongyloides (3 patients). 
Presence of pathogens by clinical severity (Truelove Witts criteria): 
Table 12: Correlation of severity of UC with pathogens 
Truelove Witts score Pathogen present Pathogen absent  
Moderate/severe UC 13 37 50 
Mild UC 2 35 37 
 15 72 87 
(p value=0.02 Two-tailed Fisher exact test) 
The presence of pathogens was very significantly associated with moderate/severe UC. 13 out of 
15 cases (86%) with pathogens had moderate to severe UC while 37 out of 72 cases (51%) 
without pathogens had moderate to severe UC. 
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DISCUSSION 
Ulcerative colitis (UC) is a chronic, remitting-relapsing type of disease. This implies that the 
patient must take medication for very long periods. The treatment of inflammatory bowel disease 
(IBD) is essentially immunosuppressive. In a tropical country like India where the incidence of 
infective colitis is very high, it is essential to demonstrate the presence of pathogens in stool in 
acute exacerbations and relapses. Treating the infection may save the patient from risks of hiking 
up the immunosuppression.  
The age of onset of symptoms of ulcerative colitis was mostly in the second and third decade of 
life. This was in keeping with previous studies (Yang SK et al and Probert CS et al) done in this 
regard126, 127. Both these studies described an almost equal sex distribution. Our study had a 
predominance of males, probably due to referral bias.  
Table 13: Clinical characteristics of our patients in comparison to previous studies 
Characteristic Jiang XL et al, 2002128 Park SH et al, 2007129 Present study 
Male: Female ratio 1.09 0.94 1.42 
Mean age at onset(yrs) 40.7 40 (Median) 35.2 + 12.6  
Proctitis 70.2% 44.1% 18.4% 
Left sided colitis 22.5% 22.7% 24.1 % 
Pancolitis 7.3% 33.2% 57.5 % 
Disease clinical severity 
Mild  - 49% 42.6% 
Moderate - 41.1% 12.6% 
Severe - 8.6% 44.8% 
The higher number of severe cases in our centre could be attributed to referral bias.  
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Parasites, cytomegalovirus and Clostridium difficile in ulcerative colitis: 
The reported incidence of such infections among IBD patients varies between 9 and 13%. A 
recent report from AIIMS found that 12% of patients with active UC had parasites, 8% had 
CMV and 10% had HSV infection73. The clinical presentation of an acute episode in a majority 
of UC patients is indistinguishable from enteric infection. Patients with ulcerative colitis often 
have intermittent flares alternating with periods of quiescent disease. Intestinal infections may be 
responsible for flares in some of these patients. Infection with intestinal parasites such as 
Entamoeba histolytica and Strongyloides stercoralis is likely to cause flares in ulcerative colitis. 
Less commonly clinically recognized are infection with cytomegalovirus and Clostridium 
difficile.  In a study from Chandigarh, C. difficile toxin was detected in the stool of 13% of 
patients with UC74. In an earlier study from northern India, 32% of active UC patients had 
parasitic or bacterial pathogens, compared to 4% of inactive UC patients75. 
The lower frequency of Clostridium difficile in our study may be related to our use of single 
stool test ELISA for toxin. Four samples on consecutive days tested for Clostridium difficile 
toxin could yield a sensitivity of 92%89. However in the study from Chandigarh by Vaishnavi et 
al74, only one stool specimen was tested for C. difficile toxin and still the frequency of detection 
was 13%. Regional variations could partly explain the lower frequency of CDT positivity, we 
observed in our study. 
We diagnosed cytomegalovirus only by cytopathic changes on histopathology analysis. 
However, a previous study by Banerjee et al73 had used both biopsy and CMV PCR from tissue 
for the same, which explains the lower yield of cytomegalovirus in our study. However, although 
8% patients were positive for CMV PCR in tissue in Banerjee’s study in comparison to our 
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2.3%, none of the patients were treated as they failed to demonstrate cytopathic changes on 
biopsy. In our institution we have a policy of treating ulcerative colitis patients for 
cytomegalovirus only when cytopathic changes, positive biopsy PCR and positive blood PBMC 
PCR (peripheral blood mononuclear cell polymerase chain reaction) are all positive. We could 
recognize two patients on biopsy, both of whom were positive for all three tests, and of whom 
one improved with ganciclovir and the other showed only temporary improvement eventually 
requiring surgery.  
The following is a graphical representation of our data in comparison with previously done 
studies in this regard. 
 
  
 
 
 
 
 
 
 
 
Figure 9: Comparison of yield of pathogens with previously done studies 
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We found in our study that the presence of pathogens was very significantly associated with 
moderate/severe UC. 86% with pathogens had moderate to severe UC while 51% without 
pathogens had moderate to severe UC.  
There is no specific persistent infection described in literature which causes IBD. But enteric 
pathogens could set the ball rolling for initiation or reactivation of quiescent disease130. Though 
most enteric infections are self-limited, these infections could initiate a cascade of inflammatory 
events leading to a chronically inflammed state or a relapse of inflammatory bowel disease in a 
genetically susceptible host (hit and run hypothesis). Thus, enteropathogenic microorganisms 
play a substantial role in the clinical initiation and relapses of IBD. 
Kochhar et al75 identified 1 patient with trophozoites of Entamoeba histolytica in 25 patients 
with active UC. Another study by Mylonaki et al131 identified 5 out of 213 patients (3 
Entamoeba histolytica, 1 each with strongyloides larvae and Blastocystis hominis). Banerjee’s 
study73 from AIIMS reported a frequency of parasites to be 12% in their patients with active 
colitis. We demonstrated 10 patients having parasites out of 87 patients (13.8%) with UC. 8 out 
of 10 patients had moderate–severe disease by Truelove Witts criteria.  
The relationship of parasitic infection to inflammatory bowel disease has evoked much interest 
since the recognition that certain helminth infections can be used to treat some patients with 
Crohn’s disease or ulcerative colitis132. Helminth parasites modulate the immune reaction and 
change it from a Th1 over-reaction to a Th2 type of reaction. This is effective therapy in a 
minority of patients with Crohn’s disease which is known to be a Th1 over-expressing disease. 
The pathogenesis of ulcerative colitis is much less clear and Th17 pathways may be involved. It 
is not yet known how much or in which direction the immune reaction (that is responsible for 
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inflammation) is altered by protozoal parasites (such as Giardia) or helminthes (such as 
Strongyloides). Nevertheless, finding such associations as we found in this study are the first step 
to elucidating the immunopathology of this interaction. 
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CONCLUSIONS 
• The presence of pathogens (parasites, cytomegalovirus and/or Clostridium difficile) was very 
significantly associated with moderate/severe UC (p value = 0.02).  
• 86% of patients testing positive for the above pathogens had moderate to severe UC while 
51% of patients without pathogens had moderate to severe UC. 
• Ten patients (11.5%) had a parasitic infestation. Eight out of these ten patients had moderate 
to severe disease.  
• Three patients (3.4%) had Clostridium difficile toxin positivity in stools. All had severe 
disease. They improved with medical treatment. 
• Two patients (2.3%) had cytopathic changes suggestive of cytomegalovirus infection on 
biopsy. Both had severe disease. One of them responded only partially to ganciclovir and 
subsequently required subtotal colectomy while the other improved with ganciclovir and 
medical therapy for ulcerative colitis 
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PATIENT’S INFORMATION SHEET AND CONSENT 
Study title:  Correlation between severity of ulcerative colitis & co-infection with parasites, 
cytomegalovirus and/or Clostridium difficile 
Principal Investigator:  Dr. Venkatakrishnan H Iyer 
INFORMATION SHEET (to be read by, or explained to the patient) 
Acute episodes of ulcerative colitis are known to be precipitated by intestinal parasites, CMV 
and clostridium difficile.  Dr. Venkatakrishnan is conducting a study to know how frequently 
these parasites and bad bacteria and viruses are present in ulcerative colitis, and whether this is 
contributing to the worsening of the disease.  
You are being asked to provide some information about your illness. The tests that are done are 
mostly those are absolutely required for your medical care, and include giving three stool 
samples for examination. In addition, you will have colonoscopy and biopsy which is also part of 
the normal care for your disease. If your biopsy shows the possible presence of virus, then you 
will be asked to undergo further tests, which again are part of the clinical care of your disease.  
The results of the tests done in connection with the study are very likely to directly benefit you. 
The information that we collect from the study will benefit other patients with the disease. 
The results of the tests will be kept confidential and there will be no direct link of the test report 
with your hospital records. 
You are free to not participate in this study if you do not so wish, and this will not affect your 
care in any way. 
CONSENT 
I hereby provide my consent for the above research study and to give the necessary information 
and samples.I also provide my consent for the stool samples to be preserved for additional 
research without my further approval, under the condition that the results will be kept 
anonymous and not linked to me. 
Name:      Hosp. No:    Study No: 
Date:     Signature: 
Witnessed by:     (Name :    ) 
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PROFORMA FOR PARASITES, C. DIFFICILE AND CMV IN ULCERATIVE COLITIS 
 
Patients Name:                                                                CMCH No:  
Contact Address:                                                             Occupation: 
                                                                                         Income/month: 
Telephone: 
E Mail: 
1. Age in years: 
2. Year of birth: 
3.  Gender: 
4. Mother Tongue: 1.Tamil  2.Telugu  3.Malayalam   4.Kannada 
                                5.Bengali    6.Oriya   7.Hindi          8.Others 
5. State Of Origin: 
6. Weight (Kg): 
7. Height (cm): 
8. Mid arm circumference: 
9. Religion:   1.Hindu    2. Muslim  3. Christian       4.Other 
10. Education: 1. None   2. I‐ V Std   3. VI‐X Std    4.Plus 2 
                        5. Graduate                        6. Post Graduate 
Patient History: 
1. At what age did the symptoms appear? 
2. At what age was the disease diagnosed? 
3. Which year was diagnosis first made? 
4. Where was the diagnosis made? 1.CMC  2.Local hospital  3.Other 
Have you ever had the following symptoms in relation to your illness? 
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5. Abdominal Pain         1.Yes              2.No 
6. Diarrhoea            1.Yes      2.No 
7. Blood in Stools         1.Yes      2.No 
8. Urgency          1.Yes      2.No 
9. Incontinence         1.Yes      2.No 
10. Tiredness           1.Yes      2.No 
11. Fever              1.Yes      2.No 
12. Intestinal Obstruction       1.Yes       2.No 
13. Have you lost weight?   1. Nil      2. <5Kg       3. 5‐10Kg      4.>10Kg      
14. What is the frequency of your stools now?   
15. Have you had anal canal lesions: 1. Fissure    2. Ulcers    3.Fistulae 
16. Have you had painful boils in legs/body:       1.Yes               2.No 
17. Have you had painful redness of eyes:           1.yes                2.No 
18. Any other problem:     
Past Medical History & Family and Personal History: 
19. Diabetes mellitus          1. Yes     2.No 
20. Hypertension           1.Yes       2.No 
21. Pulmonary tuberculosis                  1. Yes      2.No 
22. Extra Intestinal tuberculosis                      1.Yes           2.No 
23. Were you ever diagnosed to have intestinal TB?    1. Yes          2.No 
24. Have you had appendicectomy?       1. Yes         2.No 
25. If yes, was it done for acute abdominal pain?           1. Yes         2.No 
26. Have you had any other operation on abdomen?       1. Yes        2.No 
27. Has any other family member had IBD?       1. Yes          2.No 
28. Do you currently smoke cigarettes/beedies? 
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      1. No           2. <7 per week           3. 7/wk to 10/day        4.> 10/day 
29. In the past did you smoke cigarettes/beedies? 
      1. No           2. <7 per week           3. 7/wk to 10/day        4.> 10/day 
30. Did you chew tobacco alone or with paan?              1. Yes           2.No 
31. Do you take alcohol drinks? 
    1. Teetotaler   2. Social drinker   3.Moderate drinker    4.Heavy drinker 
32. What diet do you take? 
      1. Strict Vegetarian    2.Eggs also       3.Non‐vegetarian 
Medical treatment: 
33. Have you ever used aminosalicylates in the past?      1. Yes         2.No 
34. Have you ever used oral steroids in the past?              1. Yes       2.No 
35. Have you ever used rectal steroids in the past?           1. Yes       2. No 
36. Have you ever used IV steroids in the past?                1.Yes        2.No 
37. Are you currently using aminosalicylates?  1.yes    2.no   3.cannot say 
38. Are you currently using steroids (any form)? 1.yes  2.no  3.cannot say 
39. Are you currently using azathiprine/immunosuppressant?  
                                                                          1.yes    2.no   3.cannot say 
40. Have you received drugs for TB in the past? 1.yes   2.no  3.cannot say 
41. Are you currently taking drugs for TB?        1.yes   2.no   3.cannot say 
  42.Laboratory findings: 
Test  Date/Finding Report/Biopsy
Hb (g/dl)   
MCV (fL)   
ESR (mm/hr)   
CRP   
S Albumin   
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C. difficile toxin    
Stool Parasites x 3   
Endoscopy   
Colonoscopy   
Colonoscopic biopsy 
Activity 
To look for any evidence of CMV 
 
Grade (Truelove‐ Witts)   
Grade(Mayo)   
 
  
 
